Inclusion Criteria:

          -  Male or female patients, age ≥ 18 and ≤ 75 years old

          -  Written informed consent

          -  Histologically confirmed glioblastoma

          -  Patient with unmethylated MGMT (Methyl guanine methyl transferase) status

          -  Patients previously pre-treated with standard radiochemotherapy (without the
             additional cures of temozolomide.)

          -  Karnofsky Performance status ≥ 70%

          -  Life-expectancy > 3 months

          -  Adequate hematological, hepatic, and renal function.

          -  Females must be using highly effective contraceptive measures , and have a negative
             pregnancy test prior to the start of dosing if of childbearing potential, or must have
             evidence of non-childbearing potential.

        Females of childbearing potential should use reliable methods of contraception from the
        time of the screening until 5 weeks after discontinuing study treatment.

        Male patients with a female partner of childbearing potential should be willing to use
        barrier contraception during the study and for 5 months following discontinuation of study
        drug. Patients should refrain from donating sperm from the start of dosing until 5 months
        after discontinuing study treatment.

        - Affiliation to French social security or receiving such a regime.

        Exclusion Criteria:

          -  Presence of known extracranial metastatic or leptomeningeal disease Glioblastoma with
             mutated IDH1 (assessed by Immunohistochemistry)

          -  Current or recent treatment with another investigational drug

          -  Carmustine implant during surgery

          -  History of autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel
             disease…)

          -  Prohibited medications:

               1. Chronic treatment with immunosuppressive drugs

               2. Ongoing requirement for supraphysiologic steroid defined as >10 mg prednisone
                  daily (or equivalent)

               3. Treatment with therapeutic oral or IV antibiotics within 4 weeks prior to
                  enrollment. Patients receiving prophylactic antibiotics (e.g., to prevent a
                  urinary tract infection or pulmonary disease) are eligible for the study

          -  Known positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C virus
             (HCV); presence in the serum of the antigens HBs

          -  Non-hematologic toxicities Grade >1 severity (or, at the investigator's discretion,
             Grade >2 if not considered a safety risk for the patient).

          -  Patient with intra-alveolar hemorrhage, pulmonary fibrosis, or uncontrolled asthma, or
             chronic obstructive disease (COPD), defined as at least 1 hospitalization within 4
             months prior to enrollment or as at least 3 exacerbations during the last year prior
             to enrollment Hospitalization for cardiovascular or pulmonary disease within 4 weeks
             prior to enrollment.

          -  Patients with LEVF<40%

          -  Participation in a clinical study with an investigational product within 4 weeks prior
             to the start of the study treatment or patient in the exclusion period of a previous
             clinical trial.

          -  Pregnancy or lactating patients.

          -  Patients with any severe/uncontrolled inter current illness, significant co morbid or
             psychiatric conditions that in the opinion of the investigator would impair study
             participation or cooperation.

          -  Patients under guardianship, curatorship or under the protection of justice.